Striders Impex IPO...
20 Feb, 2026
Integris Medtech IPO
The Integris Medtech IPO is planned to go public with SEBI on October 9, 2025, documenting a DRHP, a 100% book-built issue, a primary equity share fresh issue of ₹925 crores, and an offer for sale (OFS) of 21,674,531 equity shares.
The price band and official subscription dates will be announced later. Each equity share has a face value of ₹1 and will be listed on the BSE and NSE. Book Running Lead Managers (BRLMs) are ICICI Securities Ltd., Axis Capital Ltd., Citigroup Global Markets India Private Ltd., and IIFL Capital Services. KFin Technologies Ltd. will serve as the offer registrar.
Company Background
Integris Medtech Ltd. was incorporated on April 25, 2008, as Integris Health Private Limited and changed its name to Integris Medtech Private Limited in June 2025, before becoming a public limited company in August 2025.
The company is headquartered in Noida, Uttar Pradesh, with a registered office in New Delhi and a corporate office in Noida. It has expanded its operations to over 65 countries as of June 30, 2025.
Operations and Product Range
Integris Medtech Ltd. is a global provider of laboratory solutions and medical products. It develops, manufactures, and sells a fully integrated portfolio across several medical segments:
- • Cardiovascular Devices: Premium devices for heart-related medical procedures.
- • Clinical Diagnostics: Devices for medical testing and disease-related diagnostics.
- • Scientific Laboratory Solutions: Sophisticated devices for research and clinical laboratories.
The company sells directly to healthcare professionals and has reached over 550 cardiologists across 250 centers within one year for specific product launches.
Facilities and Capacity
Integris Medtech has manufacturing facilities in India, Germany, and the Netherlands. These support the company’s diverse product range and global regulatory compliance, particularly for IVD products.
Brands and Market Presence
Integris Medtech has established a strong presence with flagship products, including the Protégé paclitaxel-coated balloon launched in 2024. The company created the "Minimal Metal Plasty" (MMP) market and achieved the #3 position in the Indian drug-coated balloon (DCB) market within one year. Its products are now distributed in over 65 countries.
Revenue Streams and Business Model
Revenue is generated from three main segments: cardiovascular, clinical diagnostics, and scientific laboratory solutions. For FY2025, revenue from operations was ₹2,332.81 Cr on a pro forma basis. The business model focuses on high-throughput and automated solutions, with significant revenue from global sales in the Americas, Europe, and Asia Pacific.
Management and Shareholding
Promoters include Evercure Holdings Pte. Ltd., Medicore Holdings Pte. Ltd., Gurmit Singh Chugh, and Punita Sharma. Before the IPO, the promoters and promoter group held a significant equity portion. The OFS component will dilute a portion of promoter stakes, while fresh capital will fund company expansion.
Board and Key Management
The board is led by promoters Gurmit Singh Chugh and Punita Sharma, with Darpan Batra as Group General Counsel and Compliance Officer, ensuring compliance with SEBI and Companies Act regulations while monitoring strategic initiatives.
WHAT IS GMP?
GMP (Grey Market Premium) is the difference between the IPO price and the grey market price. It is the premium amount paid for the traded IPO shares. It plays an important role in IPOs as it reflects how the IPO would react on the listing day.
A grey market is a place where shares/stocks are traded before being listed officially on the stock exchange.
Integris Medtech IPO GMP
| GMP Date | IPO Price | GMP | Last Updated |
|---|---|---|---|
| - | - | - | - |
**The GMP prices displayed here are solely for informational purposes related to the grey market news. India IPO does not engage in or facilitate grey market trading, nor are these rates (sub2) indicative of any trading activity. We also do not recommend or endorse participation in the grey market.**
Integris Medtech IPO Details
| Detail | Description |
|---|---|
| IPO Date | [.] |
| Listing Date | [.] |
| Face Value | ₹1 per Equity Share |
| Issue Price Band | [.] |
| Lot Size | [.] |
| Sale Type | Book Built Issue |
| Total Issue Size | [.] |
| Fresh Issue(Ex Market Maker) | Up to ₹925.00 Crore (₹9,250.00 Million) |
| Offer for Sale | Up to 21,674,531 Equity Shares |
| Issue Type | 100% Book Built Offer |
| Listing At | BSE and NSE |
| Share Holding Pre Issue | 10,83,38,049 shares |
Integris Medtech IPO Timeline
| Detail | Description |
|---|---|
| IPO Open Date | [.] |
| IPO Close Date | [.] |
| Tentative Allotment | [.] |
| Initiation of Refunds | [.] |
| Credit of Shares to Demat | [.] |
| Tentative Listing Date | [.] |
| Cut-off time for UPI mandate confirmation | 5:00 PM IST on the Bid/Offer Closing Date |
Integris Medtech IPO Lot Size
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Individual investors (Retail) (Min) | 1 | [.] | ₹14,000 - ₹15,000 |
| Individual investors (Retail) (Max) | 13-14 | [.] | Up to ₹2,00,000 |
| S-HNI (Min) | 14-15 | [.] | Over ₹2,00,000 |
| S-HNI (Max) | 66-70 | [.] | Up to ₹10,00,000 |
| B-HNI (Min) | 71+ | [.] | Over ₹10,00,000 |
Integris Medtech IPO Promoter Holding
| Share Holding Pre Issue | Share Holding Post Issue |
|---|---|
| Promoter Holding Pre Issue | 100% |
| Promoter Holding Post Issue | [.] |
Competitive Strength:
- • Experience in creating and marketing an integrated portfolio of medical devices and laboratory solutions in 65+ countries.
- • The presence of operational facilities in India, Germany and the Netherlands ensures a strong supply chain to support the global market.
- • Ability to rapidly gain market share, as evidenced by the achievement of the #3 position in the Indian DCB market within a year.
Integris Medtech IPO Financial Information
| Period Ended | Assets | Total Income | Profit After Tax | Net Worth | Reserves and Surplus | Total Borrowing | ||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 30 Jun 2025 | 3,340.40 | 508.93 | 267.57 | 1,807.82 | 1,804.85 | 832.14 | ||||||||||||||||||||||||||||||||||
| 31 Mar 2025 | 3,106.88 | 1,959.58 | 70.68 | 1,532.74 | 1,530.04 | 1,029.02 | ||||||||||||||||||||||||||||||||||
| 31 Mar 2024 | 2,988.58 | 1,582.26 | (4.88) | 318.99 | 316.29 | 614.32 | ||||||||||||||||||||||||||||||||||
| 31 Mar 2023 | 2,560.20 | 1,369.66 | (40.54) | 188.58 | 161.52 | 423.41 | ||||||||||||||||||||||||||||||||||
| Amount in ₹ Crore | ||||||||||||||||||||||||||||||||||||||||
Key Performance Indicator
| KPI | Values |
|---|---|
| ROE | 1.84% |
| ROCE | 1.84% |
| Debt/Equity | 0.67x |
| PAT Margin | 3.72% |
| EBITDA Margin | 16.26% |
| Pre IPO | Post IPO | |
|---|---|---|
| EPS (Rs) | ₹0.85 | [.] |
| P/E (x) | [.] | [.] |
IPO Objectives
The proceeds from the fresh issue are intended for strategic uses, including:
- • Repayment of debt (full or partial).
- • General corporate purposes.
Conclusion
Integris Medtech Ltd. is a significant global player in medical technology and laboratory solutions, with a manufacturing presence in India and Europe and a rapidly growing domestic market share in high-end cardiovascular devices.
The IPO represents a major milestone, enhancing the company’s valuation, scalability, and credibility. Its balanced focus on R&D, global exports, and domestic leadership supports its strategic execution in the evolving healthcare landscape.
IPO DRHP Status
| # | Description | Date | File |
|---|---|---|---|
| 1 | Filed with SEBI/Exchange | 09-10-2025 | - |
| 2 | SEBI/Exchange approval received | - | - |
Read more :
Frequently Asked Questions (FAQs)
-
What is the total size of the Integris Medtech IPO?
The IPO consists of a fresh issue of ₹925 crore and an offer for sale (OFS) of 21,674,531 equity shares.
-
Where are Integris Medtech Ltd.'s manufacturing facilities located?
Integris Medtech Ltd. operates manufacturing facilities in India, Germany, and the Netherlands.
-
Who are the promoters of the company for the Integris Medtech IPO?
The promoters of Integris Medtech Ltd. are Evercure Holdings Pte. Ltd., Medicore Holdings Pte. Ltd., Gurmit Singh Chugh, and Punita Sharma.
-
In how many countries does Integris Medtech Ltd. export its products?
As of June 30, 2025, the company's medical devices and laboratory solutions are sold in more than 65 countries.
-
What are the main segments of Integris Medtech Ltd.'s business?
Integris Medtech Ltd. operates in cardiovascular devices, clinical diagnostics, and scientific laboratory solutions.
-
Who is the registrar for the Integris Medtech IPO?
KFin Technologies Ltd. has been appointed as the registrar to the offer.
